natgillin/translations-raw huggingface dataset:
the C-terminal extension comprises the amino acid sequence of SEQ ID NOs: 123-268; 
C-terminalno produljenje sadrži sekvencu aminokiselina SEQ ID NOs: 123-268;
A pharmaceutical composition comprising the antagonist of claims 1-7 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak naznačen time da sadrži antagonist prema zahtjevima 1-7 i farmaceutski prihvatljivi nosač.
The antagonist of claims 1-7 for use in a method of suppressing T cell activation in a subject having a condition associated with undesired T cell activation, optionally wherein the condition associated with undesired T cell activation is an inflammatory condition, an immune and proliferative disorder, rheumatoid arthritis (RA), ankylosing spondylitis, psoriatic arthritis, osteoarthritis, osteoporosis, uveitis, inflammatory fibrosis, scleroderma, lung fibrosis, cirrhosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, asthma, allergic asthma, allergies, Chronic Obstructive Pulmonary Diases (COPD), multiple sclerosis, psoriasis, contact-mediated dermatitis, systemic lupus erythematosus (SLE) and other forms of lupus, diabetes, type I diabetes, obesity, cancer, lupus, restenosis, systemic sclerosis, scleroderma, glomerulonephritis, Sjogren syndrome, inflammatory bone resorption, transplant rejection, or graft-versus-host disease. 
Antagonist prema zahtjevima 1-7 naznačen time da je za upotrebu u suprimiranju T stanične aktivacije kod subjekta koji ima stanje koje je povezano s nepoželjnom T staničnom aktivacijom, proizvoljno gdje stanje povezano s neželjenom T staničnom aktivacijom je upalno stanje, imuni i proliferativni poremećaj, reumatoidni artritis (RA), ankilozantni spondilitis, psorijazni artritis, osteoartritis, osteoporoza, uveitis, fibroza uzrokovana upalnim stanjem, sklerodermija, fibroza pluća, ciroza, upalna bolest crijeva, Crohnova bolest, ulcerozni kolitis, astma, alergijska astma, alergije, kronična opstruktivna bolest pluća (KOPB), multipla skleroza, psorijaza, kontaktom posredovani dermatitis, sistemski eritemski lupus (SLE) i drugi oblici lupusa, dijabetes, dijabetes tip I, pretilost, karcinom, lupus, restenoza, sistemska skleroza, sklerodermija, glomerulonefritis, Sjögrenov sindrom, resorpcija kostiju koja je povezana s upalom, odbacivanje transplantata, ili bolesti presatka protiv domaćina.
A method for manufacturing a sealing joint, said method comprising coupling a first joint element (14) and a second joint element (20) to each other, whereby, in the course of the coupling, 
Postupak za proizvodnju brtvenog spoja, te navedeni postupak obuhvaća međusobno povezivanje prvog spojnog elementa (14) i drugog spojnog elementa (20), pri čemu se tijekom povezivanja,
The method according to claim 1, characterised by applying a bottom sealing member of a can (35) as a first joint element (14). 
Postupak prema zahtjevu 1, naznačen time da se kao prvi spojni element (14) primjenjuje donji element za brtvljenje limenke (35).
The method according to claim 2, characterised in that a storage unit adapted for storing a second component is connected to a can (35) adapted for storing the first component by means of the second joint element (14). 
Postupak prema zahtjevu 2, naznačen time da je jedinica za pohranjivanje prilagođena za pohranjivanje druge komponente spojene na limenku (35) koja je prilagođena za pohranjivanje prve komponente pomoću drugog spojnog elementa (14).
The method according to claim 3, characterised by applying a plastic resistant to the first component, especially to the chemicals in the first component. 
Postupak prema zahtjevu 3, naznačen time da se primjenjuje plastika otporna na prvu komponentu, naročito na kemikalije u prvoj komponenti.
The method according to any of claims 1 to 5, characterised in that the protrusion (12) is partly subjected to permanent shear deformation, and a remaining part (30) of the material of the protrusion (12) is passed through the receiving neck (15). 
Postupak prema bilo kojem od zahtjeva 1 do 5, naznačen time da se izbočina (12) djelomično podvrgava trajnoj smičnoj deformaciji, a preostali (30) materijala izbočine (12) prolazi kroz prihvatni vrat (15).
The method according to claim 8, characterised by positioning the second joint element (20) on the receiving aperture (13) prior to being pressed by means of the pressing tool (38). 
Postupak prema zahtjevu 8, naznačen time da obuhvaća namještanje drugog elementa spoja (20) na prihvatni otvor (13) prije prešanja pomoću alata za pritiskanje (38).
The method according to any of claims 1 to 11, characterised by pressing the second joint element (20) into the receiving aperture (13) at room temperature, and such a polymer is applied which is in high-elastic state at room temperature. 
Postupak prema bilo kojem od zahtjeva 1 do 11, naznačen time da sadrži prešanje drugog elementa spoja (20) u prihvatni otvor (13) kod sobne temperature, te se primjenjuje takav polimer koji je kod sobne temperature u visoko elastičnom stanju.
A sealing joint comprising a first joint element (14) and a second joint element (20) coupled to each other, wherein 
Brtveni spoj koji sadrži prvi spojni element (14) i drugi spojni element (20) koji su međusobno povezani, pri čemu je
the first joint element (14) is made of metal and comprises a receiving neck (15) having a receiving aperture (13), 
prvi spojni element (14) izrađen od metala i sadrži prihvatni vrat (15) koji ima prihvatni otvor (13),
treating the textile with a cellulose solvent comprising an amine oxide to dissolve the cellulose at a temperature of 40-120 °C, for a duration of 1-90 minutes and with a cellulose concentration in the cellulose-containing liquid phase of 0.5-35 wt.%, 
tretiranja tekstila celuloznim otapalom koji sadrži aminoksid da bi se otopi celuloza na temperaturi od 40-120 °C, u trajanju 1-90 minuta i s koncentracijom celuloze u tekućoj fazi koja sadrži celulozu od 0,5-35 wt.%,
separating a cellulose-containing liquid phase from the synthetic fibers, by decantation, centrifuge or filtration; and 
odvajanje tekućoj faze koja sadrži celulozu od sintetičkih vlakana, dekantiranjem, centrifugiranjem ili filtracijom; i
subjecting the cellulose-containing liquid phase to a cellulose spinning process to produce cellulose fibers, wherein the textile is treated with a biocatalytical or chemical solubilisation enhancer before or during the dissolution step (a) to bring the degree of polymerisation of cellulose in the range 200-1200 as measured according to ASTM D1795. 
odvajanje tekuće faze koja sadrži celulozu od sintetičkih vlakana celuloze da bi se proizvela vlakna celuloze, gdje se tekstil obrađuje s biokatalitičkim ili kemijskim pojačivačem otapanja prije ili tijekom koraka otapanja (a) kako bi se stupanj polimerizacije celuloze u rasponu 200-1200 izmjerio prema ASTM D1795.
The method according to claim 10, wherein N-methyl morpholine N-oxide is used in a mixture with water. 
Postupak sukladno patentnom zahtjevu 10, naznačen time da se N-metil morfolin N-oksid koristi za smjesu s vodom.
The method according to any one of the preceding claims, wherein in step (c) the cellulose-containing liquid phase is pumped through spinnerets, following by washing and drying of the obtained fibers. 
Postupak sukladno bilo kojem od prethodnih patentnih zahtjeva, naznačen time da se u koraku (c) tekuća faza koja sadrži celulozu pumpa kroz mlaznice, nakon čega slijedi ispiranje i sušenje dobivenih vlakana.
Aaa is an amino acid residue selected from Thr and Ser; wherein the C-terminus is a free terminus; and 
Aaa je aminokiselinski ostatak, kojeg se bira između Thr i Ser; gdje je C-kraj slobodni kraj;
inhibiting microbial infection in the intestine, preserving goblet cells in the intestine during a microbial infection, enhancing epithelial cell integrity, epithelial cell proliferation, epithelial cell differentiation, epithelial cell migration or epithelial wound healing in the intestine, in a subject in need thereof; or 
inhibicije mikrobne zaraze u crijevima, očuvanja vrčastih stanica u crijevima za vrijeme mikrobne zaraze, ojačavanja integriteta epitelnih stanica, proliferacije epitelnih stanica, diferencijacije epitelnih stanica, migracije epitelnih stanica ili zacijeljivanja epitelnih rana u crijevima, kod pojedinca kojemu je to potrebno;
treating acute kidney injury or acute pancreatitis in a subject in need thereof; or 
liječenja akutne ozljede bubrega ili akutnog pankreatitisa kod pojedinca kojemu je to potrebno;
A method for manufacturing a sealing joint, said method comprising coupling a first joint element (14) and a second joint element (20) to each other, 
Postupak za proizvodnju brtvenog spoja, te navedeni postupak obuhvaća međusobno povezivanje prvog spojnog elementa (14) i drugog spojnog elementa (20), pri čemu se tijekom povezivanja,
The method according to claim 1, characterised in that the protrusion (12) is partly subjected to permanent shear deformation, and a remaining part (30) of the material of the protrusion (12) is passed through the receiving neck (15). 
Postupak prema bilo kojem od zahtjeva 1 do 5, naznačen time da se izbočina (12) djelomično podvrgava trajnoj smičnoj deformaciji, a preostali (30) materijala izbočine (12) prolazi kroz prihvatni vrat (15).
The method according to claim 1, characterised by pressing the second joint element (20) into the receiving aperture (13) at room temperature, and such a polymer is applied which is in high-elastic state at room temperature. 
Postupak prema bilo kojem od zahtjeva 1 do 11, naznačen time da sadrži prešanje drugog elementa spoja (20) u prihvatni otvor (13) kod sobne temperature, te se primjenjuje takav polimer koji je kod sobne temperature u visoko elastičnom stanju.
A sealing joint comprising a first joint element (14) and a second joint element (20) coupled to each other, 
Brtveni spoj koji sadrži prvi spojni element (14) i drugi spojni element (20) koji su međusobno povezani, pri čemu je
Aaa′ is an amino acid residue selected from Thr and Ser; wherein the C-terminus thereof is a free terminus; 
Aaa je aminokiselinski ostatak, kojeg se bira između Thr i Ser; gdje je C-kraj slobodni kraj;
a transmission power value of the A-SRS received in response to the TPC command transmitted in a non-specific subframe is based on a first accumulation value of the TPC command, and a transmission power value of the A-SRS received in response to the TPC command transmitted in a specific subframe is based on a second accumulation value of the TPC command, which is calculated differently from the first accumulation value. 
kontroliranje vrijednosti snage prijenosa A-SRS-a koristeći prvu akumulacijsku vrijednost ažuriranu primljenom TPC naredbom; i odašiljanje A-SRS-a s navedenom vrijednošću snage prijenosa naznačeno time da navedeni korak kontrole koristi drugu akumulacijsku vrijednost umjesto prve akumulacijske vrijednosti, druga akumulacijska vrijednost se ažurira s TPC naredbom koja se prenosi na određenom podokviru i u određenom formatu za kontrolnu informaciju silazne veze DCI.
longitudinal axes (LA1, LA2, LA3) of the connections (AS1, AS2, AS3) are located substantially in a first plane (E1); 
– uzdužne osi (LA1, LA2, LA3) spojeva (AS1, AS2, AS3) se uglavnom nalaze u prvoj ravnini (E1);
Pipe connector (RVS) according to claim 1, wherein the longitudinal axes (LA1, LA2) of the first connection (AS1) and the second connection (AS2) are aligned parallel to one another. 
Konektor za cijevi (RVS) u skladu s patentnim zahtjevom 1, naznačen time što su uzdužne osi (LA1, LA2) prvog spoja (AS1) i drugog spoja (AS2) poravnane paralelno jedna u odnosu na drugu.
Pipe connector (RVS) according to any one of claims 1 to 6, wherein the first connection (AS1) and/or the second connection (AS2) are suitable for connecting pipe lines (RL), in particular by means of compression and/or a quick connect procedure. 
Konektor za cijevi (RVS) u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što su prvi spoj (AS1) i/ili drugi spoj (AS2) pogodni za spajanje cijevnih linija (RL), osobito komprimiranjem i/ili postupkom brzog spajanja.
Pipe connector (RVS) according to any one of claims 1 to 11, wherein the pipe connector (RVS) is suitable for connection to a connection element (AK) of a concealed fitting. 
Konektor za cijevi (RVS) u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time što je konektor za cijevi (RVS) pogodan za spajanje sa spojnim elementom (AK) podžbukne armature.
Arrangement with a pipe connector (RVS) according to any one of claims 1 to 12 and with a concealed fitting, wherein the pipe connector (RVS) is screwed by way of the thread of the third connection (AS3) in a connection of a connection element (AK) of the concealed fitting, in particular a hot or cold water connection. 
Uređaj s konektorom za cijevi (RVS) u skladu s bilo kojim od patentnih zahtjeva 1 do 12 i s podžbuknom armaturom, naznačen time što je konektor za cijevi (RVS) navijen navojem trećeg spoja (AS3) u spoju spojnog elementa (AK) podžbukne armature, osobito za spajanje vruće ili hladne vode.
hydrolyzing the intermediate from step a) with an aqueous solution at a pH comprised from 0 to 7 by adding water or a diluted alkaline solution, freeing the hydroxyls from the boron-containing protective groups, obtaining the acetyloxy derivative of Compound (II) and optional recovery of the boron derivative; 
hidroliziranje intermedijera iz koraka a) s vodenom otopinom kod pH koji je u opsegu od 0 do 7 dodavanjem vode ili razrijeđene lužnate otopine, oslobađanje hidroksila iz zaštitnih skupina koje sadrže bor, dobivanje acetiloksi derivata spoja (II) i proizvoljno obnavljanje derivata bora;
The process according to any one of claims 10 or 11 which comprises boronic acid recovery by co-solvent extraction, wherein said co-solvent is an organic water-immiscible solvent selected in the group consisting of: 4-methyl-2-pentanone, 2-pentanone, 3-pentanone, dibutyl ether, 2-methyltetrahydrofurane, ciclopentylmethyl ether, methyl isopropyl ketone, methyl isopentyl ketone, ethyl acetate, butyl acetate, pentyl acetate, isopentyl acetate, isopropyl acetate. 
Postupak prema bilo kojem od zahtjeva 10 ili 11 koji sadrži ponovno dobivanje boronične kiseline pomoću ekstrakcije sa kootapalom, naznačen time da je navedeno kootapalo je organsko otapalo koje se ne miješa s vodom odabrano iz skupine koja sadrži: 4-metil-2-pentanon, 2-pentanon, 3-pentanon, dibutil eter, 2-metiltetrahidrofuran, ciklopentilmetil eter, metil izopropil keton, metil izopentil keton, etil acetat, butil acetat, pentil acetat, izopentil acetat, izopropil acetat.
The process according to claim 7, wherein said Compound of formula (IV) is prepared submitting to iodination the following Compound (V): 
Postupak prema zahtjevu 7, naznačen time da se navedeni spoj s formulom (IV) priprema podvrgavanjem jodiranju sljedećeg spoja (V):
The process according to claim 14, wherein said Compound (V) is prepared according to the following reaction scheme: wherein: 
Postupak prema zahtjevu 14, naznačen time da se navedeni spoj (V) priprema prema sljedećoj reakcijskoj shemi: pri čemu:
5-nitroisophthalic acid is treated with an R1OH alcohol, wherein R1 is a linear or branched C1-C4alkyl, to provide the corresponding diester; 
5-nitroizoftalna kiselina se obrađuje s R1OH alkoholom, pri čemu R1 je ravni ili razgranati C1-C4alkil, da se dobije odgovarajući diester;
ii) the 5-nitro group is reduced to the corresponding 5-amino group to provide the Compound (VII); 
ii) 5-nitro skupina se reducira u odgovarajuću 5-amino skupinu da se dobije spoj (VII);
iii) the diester is reacted with 2-amino-1,3-propandiol to provide the Compound (V). 
iii) diester reagira s 2-amino-1,3-propandiolom da se dobije spoj (V).
A process for the preparation of lopamidol (II) according to the following reaction scheme: wherein: 
Postupak za pripremu jopamidola (II) prema sljedećoj reakcijskoj shemi: naznačen time da:
5-nitroisophthalic acid (5-NIPA) is treated with an R1OH alcohol, wherein R1 is a linear or branched C1-C4alkyl, to provide the diester (VI); 
se 5-nitroizoftalna kiselina (5-NIPA) obrađuje s R1OH alkoholom, pri čemu R1 je ravni ili razgranati C1-C4alkil, da se dobije diester (VI);
The Compound of claim 19, wherein X is selected in the group consisting of: phenyl, methyl substituted phenyl, methyl and butyl. 
Spoj prema zahtjevu 19, naznačen time da je X odabran iz skupine koja sadrži: fenil, metil supstituirani fenil, metil i butil.
The use of the Compound of formula (I) according to claims 20-21 and N-(S)-2-(acetyloxy)propanoyl derivative thereof as intermediate in the synthesis of lopamidol (II). 
Uporaba spoja s formulom (I) prema zahtjevima 20-21 i njegovog derivata N-(S)-2-(acetiloksi)propanoila kao intermedijera u sintezi jopamidola (II).
A self-sealing dressing (10) adapted for negative pressure wound therapy, for application to skin of a human being in the form of a laminate comprising: 
Samoljepljivi zavoj (10) prilagođ za terapiju rana od negativnog tlaka, namijenjen za primjenu na ljudskoj koži, i u obliku laminata koji obuhvaća:
The dressing (10) of claim 1, wherein a minimum thickness of the combination of the substrate (12) and the adhesive layer (18) is about 8 µm. 
Zavoj (10) sukladno patentnom zahtjevu 1, naznačen time, da je minimalna debljina kombinacije supstrata (12) i ljepljivog sloja (18) oko 8 μm.
The dressing (10) of claim 1, wherein the substrate (12) has a thickness about 1.2-1.9 times greater than a thickness of the adhesive layer (18). 
Zavoj (10) sukladno patentnom zahtjevu 1, naznačen time da je debljina (12) supstrata oko 1.2-1.9 puta veća od debljine ljepljivog sloja (18).
The dressing (10) of claim 1, wherein the substrate (12) has a shore hardness of about 30A and an elongation to failure of about 800%. 
Zavoj (10) sukladno patentnom zahtjevu 1, naznačen time da zavoj ima Shore tvrdoću supstrata (12) od oko 30A i izduženje pri kidanju od oko 800%.
The dressing (10) of claim 1, wherein the substrate (12) includes a region at the rear surface (16) that is adjacent the adhesive layer (18) and includes voids at least partially filled with adhesive material. 
Zavoj (10) sukladno patentnom zahtjevu 1, naznačen time da supstrat (12) obuhvaća područje na polju stražnje površine (16) koji je susjedan ljepljivom sloju (18) i sadrži šupljine barem djelomično ispunjene ljepljivim materijalom.
The dressing (10) of claim 1, wherein the adhesive layer (18) has a thickness of less than about 5 µm. 
Zavoj (10) sukladno patentnom zahtjevu 1, naznačen time da je ljepljivi sloj (18) debljine manje od oko 5 μm.
The dressing (10) of claim 1, wherein when the dressing (10) is adhered to the skin by the adhesive layer (18), the dressing (10) has a peel strength of about 0.1-2 N/in. 
Zavoj (10) sukladno patentnom zahtjevu 1, naznačen time da priliko prijanjanja zavoja (10) na kožu uz pomoć ljepljivog sloja (18), zavoj (10) koji ima snagu ljuštenja od oko 0.1-2 N/in.
An antibody according to claim 1 wherein the antibody does not directly bind to any one of residues Q20, G120, Q16, N124. 
Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što se protutijelo ne veže izravno na bilo koji od ostataka Q20, G120, Q16, N124.
ID. NO:73 and a light chain variable region encoded by SEQ. 
ID. NO:73 i varijabilno područje lakog lanca kojeg kodira SEQ.
ID. NO:74 and a light chain variable region of SEQ. 
ID. NO:74 i varijabilno područje lakog lanca sa SEQ.
ID. NO:76 and a light chain region of SEQ. 
ID. NO:76 i područje lakog lanca sa SEQ.
A recombinant transformed, transfected or transduced host cell comprising at least one expression cassette, whereby said expression cassette comprises a polynucleotide encoding a heavy chain of an antibody according to claim 8 and further comprises a polynucleotide encoding a light chain of an antibody or according to claim 8. 
Rekombinantna transformirana, transficirana ili transduciran stanica domaćin, naznačena time što ima najmanje jednu ekspresijsku kasetu, gdje navedena ekspresijska kaseta sadrži polinukleotid koji kodira teški lanac protutijela u skladu s patentnim zahtjevom 8 i dodatno sadrži polinukleotid koji kodira laki lanac protutijela ili u skladu s patentnim zahtjevom 8.
The host cell according to claim 13 wherein the cell is CHO or NSO. 
Stanica domaćin u skladu s patentnim zahtjevom 13, naznačena time što je stanica CHO ili NSO.
The pharmaceutical composition according to claim 15 for use in the treatment of a human patient afflicted with an inflammatory disorder or disease. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 15, naznačen time što je namijenjen upotrebi u liječenju ljudskog pacijenta koji boluje od upalnog poremećaja ili bolesti.
The pharmaceutical composition of claim 16 for use in the treatment of a human patient afflicted with an inflammatory arthropathy, rheumatoid arthritis, osteoarthritis, idiopathic pulmonary fibrosis (IPF), Systemic sclerosis, Sjogrens syndrome, Scleroderma and/or psoriasis. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 16, naznačen time što je namijenjen upotrebi u liječenju ljudskog pacijenta koji boluje od upalne artropatije, reumatoidnog artritisa, osteoartritisa, idiopatske plućne fibroze (IPF), sistemne skleroze, Sjögrenovog sindroma, skleroderme i/ili psorijaze.
provided that 
pod uvjetom da su
A compound according to any one of claims 1 to 11 for use in the treatment or prophylaxis of pain, atherosclerosis, age-related macular degeneration, diabetic retinopathy, glaucoma, retinal vein occlusion, retinopathy of prematurity, ocular ischemic syndrome, geographic atrophy, diabetes mellitus, inflammation, inflammatory bowel disease, ischemia-reperfusion injury, acute liver failure, liver fibrosis, lung fibrosis, kidney fibrosis, systemic fibrosis, acute allograft rejection, chronic allograft nephropathy, diabetic nephropathy, glomerulonephropathy, cardiomyopathy, heart failure, myocardial ischemia, myocardial infarction, systemic sclerosis, thermal injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or tumors, regulation of bone mass, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, Parkinson's disease, stroke, transient ischemic attack or uveitis. 
Spoj prema bilo kojem od zahtjeva 1 do 11, naznačen time, da se upotrebljava za liječenje ili profilaksu boli, ateroskleroze, staračke makularne degeneracije, dijabetičke retinopatije, glaukoma, retinalne venske okluzije, retinopatije nedonoščadi, okularnog ishemijskog sindroma, geografske atrofije, šećerne bolesti, upale, upalne bolesti crijeva, ishemijskih reperfuzijskih ozljeda, akutnog zatajenja jetre, jetrene fibroze, plućne fibroze, fibroze bubrega, sustavne fibroze, akutnog odbijanja alogenskog presatka, kronične nefropatije alogenskog presatka, dijabetičke nefropatije, glomerulonefropatije, kardiomiopatije, zatajenja srca, miokardijalne ishemije, miokardijalnog infarkta, sustavne skleroze, toplinskih ozljeda, opeklina, hipertrofičnih ožiljaka, keloida, pireksije gingive, jetrene ciroze ili tumora, u regulaciji koštane mase, amiotrofične lateralne skleroze, multiple skleroze, Alzheimerove bolesti, Parkinsonove bolesti, moždanog udara, prolaznog ishemijskog napadaja ili uveitisa.
A pharmaceutical composition comprising N-acetyl-3-(4'-aminophenyl)-2-methoxypropionic acid, or a pharmaceutically acceptable salt or a stereoisomer thereof, and a pharmaceutically acceptable excipient, for use in treating or ameliorating lichen planopilaris in a patient in need thereof, wherein the composition is for topical administration to said patient. 
Farmaceutski sastav koji sadrži N-acetil-3-(4'-aminofenil)-2-metoksipropionsku kiselinu, ili njezinu farmaceutski prihvatljivu sol ili stereoizomer, i farmaceutski prihvatljivi ekscipijens, za uporabu u liječenju ili poboljšanju lichen planopilarisa kod pacijenta kojem je to potrebno, gdje je sastav za topikalnu primjenu spomenutom pacijentu.